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Abstract 29 
For influenza A and B viruses to be infectious they require eight viral RNA (vRNA) genome 30 
segments to be packaged into virions. For efficient packaging influenza A viruses utilise cis-acting 31 
vRNA sequences, containing both non-coding and protein coding regions of each segment. 32 
Whether influenza B viruses have similar packaging signals is unknown. Here we show that coding 33 
regions at the 3’ and 5’ ends of the influenza B virus vRNA segment four are required for genome 34 
packaging, with the first 30 nucleotides at each end essential for this process. Synonymous 35 
mutation of these regions led to virus attenuation, an increase in defective particle production and 36 
a reduction in packaging of multiple vRNAs. Overall our data suggest that the influenza B virus 37 
vRNA gene segments likely interact with each other during the packaging process, which is driven 38 
by cis-acting packaging signals that extend into protein coding regions of the vRNA. 39 
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 56 
 57 
Introduction 58 
Influenza A and B viruses are members of the Orthomyxoviridae family, containing an eight-59 
segmented negative sense RNA genome. Each segment encodes one or more proteins that show 60 
high levels of similarity in structure and function between the two types of viruses, despite 61 
significant differences in amino acid identity (Palese & Shaw, 2007). Influenza A and B virions also 62 
show high levels of structural similarity, however a significant difference has been observed in 63 
genome arrangement within the core. The genome of both viruses is in the form of eight viral 64 
ribonucleoprotein complexes (vRNP) consisting of the viral RNA (vRNA) encapsidated by 65 
nucleoprotein and associated with a heterotrimeric polymerase complex. Electron microscopic 66 
analysis of influenza A virus particles demonstrated that the vRNPs are arranged in a highly 67 
ordered “7+1” orientation in which all segments align in a circular fashion with one segment in the 68 
centre (Noda et al., 2006). However recent evidence suggests that this does not occur in influenza 69 
B viruses, as the vRNPs appear to twist around each other (Katz et al., 2014). This suggests that 70 
influenza A and B viruses potentially adopt different mechanisms for genome packaging. 71 
 72 
It is now widely accepted that influenza A viruses utilise a selective packaging process by which a 73 
single copy of each of the vRNPs is packaged into progeny virions in a process likely driven by 74 
bipartite cis-acting sequences within the vRNAs (Gerber et al., 2014). Although early work 75 
suggested that the non-coding regions at the extreme termini of each vRNA were the minimal 76 
determinants of genome packaging (Luytjes et al., 1989), more recent studies have shown that the 77 
extreme 5’ and 3’ ends of the protein coding regions are required for optimal genome packaging 78 
(reviewed in Hutchinson et al., 2010). These cis-acting sequences are hypothesized to be 79 
responsible not only for packaging each genome segment into the virion but also for forming 80 
interactions between segments (Fournier et al., 2012) to create a complex of vRNPs, thereby 81 
acting as bundling signals to allow a single copy of each vRNP to be packaged (Goto et al., 2013). 82 
It is tempting to speculate that this may be responsible for the “7+1” genome arrangement, which 83 
questions whether influenza B viruses contain similar cis-acting packaging sequences due to the 84 
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significantly different appearance of the vRNPs within the virions. Although mutagenesis of the 85 
non-coding regions of the influenza B virus vRNA segment four suggested these regions are 86 
necessary for genome packaging and may therefore act as cis-acting packaging signals (Barclay & 87 
Palese, 1995), whether these signals include protein coding regions similar to their influenza A 88 
virus counterparts, is unknown. 89 
 90 
Here we address this by analysing the role of the terminal protein coding regions of vRNA segment 91 
four of influenza B viruses in genome packaging. We show that the first and last 150 nt of the 92 
influenza B virus haemagglutinin (BHA) open reading frame are required for efficient packaging of 93 
a viral-like RNA into virus-like particles and that the first 30 nt of the BHA ORF at the 3’ end of the 94 
negative sense vRNA are essential for this function. Analysis of mutant viruses containing 95 
synonymous mutations in these regions demonstrated that mutations in the terminal 30 nt of the 96 
protein coding region at both the 3’ and 5’ ends of vRNA segment four led to virus attenuation, an 97 
increase in defective particle production and a reduction in packaging of multiple vRNA segments. 98 
Our findings give the first evidence of the role of influenza B virus protein coding regions in 99 
ensuring optimal genome packaging. 100 
 101 
Results and discussion 102 
A series of constructs were created for use in a mini-genome reporter assay (Sherry et al., 2014) 103 
to assess the importance of the terminal ends of the coding regions of influenza B virus vRNA 104 
segment four (which encodes the haemagglutinin protein; BHA) in genome packaging. To create 105 
the constructs the GFP coding sequence was flanked by the vRNA segment four non-coding 106 
regions and the terminal 150 nucleotides at both termini of the BHA coding region, followed by 107 
insertion into the pHH-21 plasmid in a 3’-5’ negative sense orientation, thereby allowing expression 108 
of a negative sense mini-genome vRNA segment (Fig. 1a). A series of truncations or deletions 109 
were then introduced into the BHA coding regions at either terminus. The mini-genome assay 110 
demonstrated the viral-like RNAs encoded on each construct expressed similar levels of GFP (Fig. 111 
1b). The ability of each of these viral-like RNAs to be packaged into virus particles was assessed 112 
by transfecting the constructs into 293T cells followed by infection with B/Yamanashi/98 virus and 113 
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the resultant virus-containing supernatant used to infect MDCK cells for FACS analysis. To 114 
determine the level of infectious virus present in the 293T cell supernatants the samples were 115 
serially 2-fold diluted and used to infect MDCK cells. At 10 hours post-infection (h.p.i.) cells were 116 
subjected to immunofluorescence analysis using an anti-BNP antibody to determine the number of 117 
virus antigen-positive cells. The dilution of supernatant that resulted in infection of 80-90% of cells 118 
was then placed onto fresh MDCK cells and at 10 h.p.i. cells were subjected to 119 
immunofluorescence and FACS analysis. Figure 1(c) shows representative GFP and viral antigen 120 
staining for cells infected with four of the supernatant samples. FACS analysis was performed to 121 
quantify the percentage of infected cells expressing GFP. 56% of virus-infected MDCK cells 122 
expressed the full-length HA(150)GFP(150) mini-genome vRNA segment, demonstrating the 123 
maximum packaging efficiency when using this approach, which is analogous to the level of 124 
packaging observed in a similar study using influenza A viruses (Fujii et al., 2005). The packaging 125 
levels of all other segments were expressed as a percentage of the full-length mini-genome 126 
segment (Fig. 1d). Removal of the 150 nucleotide BHA coding region at the 3’ end of the vRNA 127 
reduced the packaging efficiency to less than 1%, which could only be increased if the first 30 128 
nucleotides of the this region were retained. When the 150 nucleotide BHA coding region at the 5’ 129 
end of the vRNA was removed the packaging efficiency dropped to 9%, indicating that truncation 130 
at the 3’ end of the vRNA had a larger effect on packaging. However when the terminal 30 131 
nucleotides of the BHA coding region at the 5’ end of the vRNA were replaced (HA(150)GFP(30)) 132 
packaging efficiency was increased to 73%. Overall the data indicate that although the entire 150 133 
nucleotide regions at both ends of the BHA coding region are required for efficient genome 134 
packaging, the terminal 30 nucleotides at each end have a significant effect on this process, with 135 
those at the 3’ end having the greatest effect on packaging efficiency. These findings are similar to 136 
those observed for packaging of various influenza A virus segments (Fujii et al., 2005; Fujii et al., 137 
2003), suggesting that influenza B viruses may adopt a similar mechanism of genome packaging 138 
to their influenza A virus counterparts. 139 
 140 
To assess the effects of the BHA coding regions on genome packaging in the context of infectious 141 
virus a series of mutant viruses were created in which synonymous mutations were introduced into 142 
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the first 30 nucleotides of the BHA coding region at the 3’ end of the negative sense vRNA (3m30 143 
mutations) or between nucleotides 31-60 (3m60 mutations) (Fig. 2a). Similar mutations were 144 
introduced into the BHA coding region at the 5’ end of the negative sense vRNA. Viruses were 145 
generated containing mutations at either one or both termini. The rBHA-3m30/5m30 virus took 146 
significantly longer to recover due to a propensity to generate defective particles, therefore this 147 
virus was plaque purified to remove these particles prior to experimentation. The only virus 148 
containing mutations at a single end of the gene that demonstrated attenuated replication kinetics 149 
compared to the rBHA wt (wild type) virus was the rBHA-3m30 virus (Fig. 2b). Further attenuation 150 
was observed when combining the 3m30 mutation with mutations in the BHA coding region at the 151 
5’ end of the vRNA, with the rBHA-3m30/5m30 virus demonstrating the largest degree of 152 
attenuation (Fig. 2c). This confirmed that the terminal 30 nucleotides at both ends of the BHA 153 
coding region have a significant effect on virus replication. This is remarkably similar to the results 154 
of a previous study in which the packaging signals of the influenza A virus segment eight were 155 
characterised (Fujii et al., 2005). In this study synonymous mutations introduced into the 5’ end of 156 
the coding region did not alter viral replication, whereas mutations in the 3’ end of the coding 157 
region resulted in a slight attenuation, which was enhanced by introducing the mutations into both 158 
the 3’ and 5’ coding regions. The phenotype of the double mutant reported by Fujii et al. was 159 
therefore remarkably similar to the rBHA-3m30/5m30 virus, suggesting these sequences are 160 
essential for efficient viral replication of both influenza A and B viruses, possibly indicating similar 161 
functional requirements.  162 
 163 
As the 3m30/5m30 mutations may have reduced the efficiency of genome packaging, resulting in 164 
higher levels of defective virus production, the particle to infectivity ratio of all viruses stocks was 165 
analysed. The only virus that demonstrated a marked increase in the number of defective particles 166 
was the rBHA-3m30/5m30 virus (Fig. 2d). The 36 and 48 hour time point samples (Fig. 2a and b) 167 
of viruses containing the 3m30 mutations were analysed for particle to infectivity ratios. The only 168 
virus that demonstrated a significant increase in defective particles at both time points was the 169 
rBHA-3m30/5m30 virus (Fig 2e). The level of defective virus particles increased for all viruses 170 
between the two time points, however while most viruses demonstrated a 2- to 7-fold increase, 171 
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there was a 39-fold increase in rBHA-3m30/5m30 defective particles. The propensity for this virus 172 
to generate defective particles was likely responsible for its attenuation in the replication analysis. 173 
 174 
Sequence analysis of vRNA segment four of multiple influenza B viruses isolated between 1940 175 
and 2014 shows that the 3m30, 3m60, 5m30 and 5m60 regions of the genome are highly 176 
conserved, with the 3m30 region completely conserved in all analysed sequences (Fig. 3a). The 177 
lack of synonymous mutations in the 3m30 region over a 74-year time period may suggest that the 178 
sequence integrity of the RNA in this region is essential for virus viability, potentially through 179 
contributing to efficient genome packaging. This is not surprising given that previous studies have 180 
shown that the areas of various influenza A virus vRNA segments that contain the highest levels of 181 
sequence conservation are found in the terminal ends of the coding regions that have been 182 
implicated as packaging signals (Gog et al., 2007; Marsh et al., 2007). As the mutated regions of 183 
the rBHA-3m30/5m30 virus potentially represent packaging signals, changes in RNA sequence or 184 
secondary structure may have reduced the efficiency of segment four packaging. However it was 185 
also possible that such changes had affected the efficiency of mRNA transcription from the mutant 186 
vRNA, thereby leading to viral attenuation. To address this vRNA segment four from the wt and 187 
rBHA-3m30/5m30 viruses was cloned into a plasmid under the control of the human RNA 188 
polymerase I promoter allowing its expression in a mini-genome assay. The results showed similar 189 
levels of BHA for both wt and mutant segments (Fig. 3b and c). This demonstrated that the 190 
3m30/5m30 mutations did not affect the ability of the polymerase to transcribe BHA mRNA and 191 
therefore did not affect BHA protein levels. 192 
 193 
To analyse whether the BHA-3m30/5m30 mutations reduced vRNA content in released virions, 194 
resulting in increased levels of defective particles shown in Fig. 2(d), the BNP and vRNA levels in 195 
wt and mutant virions were assessed. After purification of the viruses an equal number of wt and 196 
mutant virions (determined by haemagglutination assay) were analysed for protein content by 197 
SDS-PAGE and coomassie staining. BHA was present in the trypsin-cleaved form of BHA1 and 198 
BHA2 (Fig. 3d). A slight reduction in overall viral protein levels were observed in the mutant virions 199 
compared to those of rBHA wt, suggesting the presence of fewer particles, however a greater 200 
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reduction was observed in BNP levels compared to other proteins. To accurately identify the viral 201 
proteins and to quantify their levels in both viruses the viral proteins were analysed by 202 
immunoblotting. While BM1 and BHA levels were similar for both viruses the BNP level in the 203 
mutant was only 63% that of wt (Fig. 3e). As BNP is associated with the viral genome this 204 
reduction likely indicated reduced vRNA content in the virions. This was confirmed by qRT-PCR 205 
analysis (Fig. 3f). Levels of three vRNA segments were present in the mutant virions at only 56 to 206 
74% those of wt virus, which is a similar reduction to the levels of BNP observed in Fig. 3(e). This 207 
demonstrated a genome packaging deficiency in the mutant, and suggested that the deficiency in 208 
packaging segment four also reduced packaging of other segments. It has been suggested that 209 
intermolecular interactions form between influenza A virus vRNPs such that the full complement of 210 
vRNPs are present as a complex prior to packaging into virions (Goto et al., 2013). A reduction in 211 
packaging efficiency of a single segment could therefore reduce or even prevent packaging of 212 
other segments. It is possible that this is also true of influenza B virus vRNPs and the mutation of 213 
packaging signals in the rBHA-3m30/5m30 virus segment four reduced the packaging of multiple 214 
segments. This would explain the increased level of defective particles and virus attenuation 215 
observed in Fig. 2, however whether the defective particles were semi-infectious as they lacked 216 
one or more vRNA segment, or lacked genome altogether is unknown. The level of vRNA segment 217 
eight was reduced to a larger extent than the other segments. Similar variations in packaging 218 
efficiencies between influenza A virus vRNPs have been described (Marsh et al., 2007), further 219 
suggesting that influenza B virus genome packaging may adopt similar mechanisms to that of 220 
influenza A viruses, potentially indicating the likelihood of direct interactions between specific 221 
vRNPs during influenza B virus packaging. 222 
 223 
It is not surprising that studies in recent years have identified coding regions in the influenza A 224 
virus vRNA as being important for efficient genome packaging, as prior work had shown that 225 
defective viruses containing truncated gene segments retained a full complement of eight vRNPs, 226 
with the defective segment retaining both the non-coding regions and a portion of the coding 227 
regions at either terminus (Duhaut & Dimmock, 1998; Duhaut & McCauley, 1996; Nayak et al., 228 
1982), with these coding regions increasing the stability of the defective particles (Duhaut & 229 
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Dimmock, 2000). It is plausible that short coding regions were retained as they contained the cis-230 
acting packaging signals. Similar findings have been observed in defective influenza B viruses 231 
containing truncations in vRNA segment four, with the first and last 150-200bp of the BHA ORF 232 
retained (DJ unpublished results). This along with the data shown above suggests that influenza B 233 
viruses do contain similar genome packaging signals to those observed for influenza A viruses, 234 
and that these signals extend into the coding regions. Our results show that the extreme terminal 235 
3’ and 5’ ends of the coding regions of the influenza B virus vRNA segment four are required for 236 
efficient genome packaging, with the first 30 nucleotides at the 3’ end having the greatest influence 237 
on packaging efficiency, similar to findings in the context of influenza A virus segments six and 238 
eight packaging (Fujii et al., 2005; Fujii et al., 2003). It was previously shown through truncation 239 
analysis that the terminal 3’ and 5’ ends of the coding region of the influenza A virus segment four 240 
are required for efficient packaging to occur (Marsh et al., 2007; Watanabe et al., 2003). However 241 
unlike the findings for influenza B virus segment four, systematic synonymous mutagenesis in the 242 
influenza A virus segment revealed that a 15 nucleotide stretch in the terminal 80 nucleotides at 243 
the 5’ end of the coding region had the greatest influence on packaging efficiency (Marsh et al., 244 
2007). Unfortunately the studies of Marsh et al. did not include analysis of viruses containing 245 
synonymous mutations at both the 3’ and 5’ ends of the same segment, therefore it is unknown 246 
whether this would have enhanced the attenuation of a recombinant virus, similar to the rBHA-247 
3m30/5m30 virus in the current study. It is likely that these differences in segment four packaging 248 
sequence requirements between the two viruses are influenced by the mechanism of vRNA 249 
interaction between the individual segments, especially as it has been reported that vRNPs interact 250 
during transport to the site of assembly (Chou et al., 2013; Gavazzi et al., 2013; Lakdawala et al., 251 
2014). Although our results suggest that the mechanism of genome packaging utilised by influenza 252 
A and B viruses is similar, the fact that the 3’ end of the coding region was more important in 253 
packaging of influenza B virus vRNA segment four compared to the 5’ end in influenza A viruses 254 
may suggest that there is a difference in the mechanism behind vRNA-vRNA interaction formation 255 
between the two viruses, or that the influenza B virus vRNA segment four interacts with different 256 
vRNPs compared to its influenza A virus counterpart. Further experiments using labelled vRNPs 257 
(Lakdawala et al., 2014) could address this. Furthermore while EM comparisons of vRNP structural 258 
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arrangement in influenza A and B virions might suggest different mechanisms of genome 259 
packaging between the two viruses (Katz et al., 2014; Noda et al., 2006), our results suggest a 260 
similar mechanism of cis-acting RNA signal-mediated packaging is employed by both viruses. The 261 
difference in vRNP arrangement is likely due to vRNA-vRNA interactions differing between the two 262 
viruses, leading to the more twisted vRNP complex observed in influenza B viruses. 263 
 264 
Overall we propose that the 3’ and 5’ ends of the coding region of the influenza B virus vRNA 265 
segment four contains cis-acting packaging signals and that mutations in the first 30 nucleotides of 266 
these regions reduce the efficiency of genome packaging into progeny virions by approximately 267 
40%, similar to that observed for mutagenesis of packaging signals in the same segment of 268 
influenza A virus (Marsh et al., 2007). This reduction in segment four packaging subsequently 269 
reduces the packaging of other segments, resulting in an increase in the release of defective 270 
particles, thereby attenuating the virus. It is important to fully characterise the cis-acting packaging 271 
signals in influenza B viruses as this could have significant consequences for vaccine production. 272 
Contemporary influenza B viruses replicate poorly in eggs and therefore introducing segments four 273 
and six (encoding the BHA and BNA proteins respectively) into the background of a virus adapted 274 
for efficient growth in eggs by reverse genetics could offer significant advantages for vaccine 275 
production purposes (Hoffmann et al., 2002). However natural mutations in the coding regions of 276 
these segments may reduce the efficiency of vRNA packaging, which has previously been shown 277 
to be a limiting factor in influenza A virus reassortment (Essere et al., 2013). Therefore ensuring 278 
these signals are optimal for efficient recombinant virus generation could enhance vaccine seed 279 
production. 280 
 281 
Materials and methods 282 
Cells and Viruses 283 
293T and MDCK cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 284 
(Invitrogen) supplemented with 10% foetal calf serum (FCS) at 37  °C with 5% CO2. 285 
B/Yamanashi/98 wild-type (rBHA wt) and mutant viruses were generated using plasmid-based 286 
reverse genetics as previously described (Hoffmann et al., 2002). Briefly, 293T cells were 287 
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transfected with eight genome-encoding bi-directional (pAB) plasmids using FuGENE 6 288 
transfection reagent (Promega) and at 16 h post-transfection the cells were co-cultured with MDCK 289 
cells in serum-free DMEM containing 2.5 µg/mL N-acetyl trypsin (Sigma). Supernatants were 290 
harvested four days post-transfection, viruses propagated twice through MDCK cells followed by 291 
plaque assay titration on MDCK cells. Viral RNA was extracted using the QIAamp viral RNA kit 292 
(QIAGEN), vRNA segment four of each virus was amplified by reverse-transcriptase PCR using 293 
genome specific primers and the resultant DNA sequenced to confirm presence of the desired 294 
mutations.  295 
 296 
Plasmids 297 
To create the pHH-HA(150)GFP(150) mini-genome plasmid the 3’ and 5’ non-coding regions of 298 
B/Yamanashi/98 vRNA segment four flanked by 150nt of the BHA coding region at either end of 299 
the gene segment were amplified by PCR using the parental pAB-HA plasmid as template. The 300 
eGFP coding sequence was amplified by PCR and inserted between the 3’ and 5’ end BHA PCR 301 
products by overlapping PCR. A translation termination codon was inserted after the GFP ORF. 302 
The entire HA(150)GFP(150) PCR product was inserted into the pHH-21 reverse genetics vector 303 
between BsmBI restriction sites in a negative sense orientation such that expression of the 304 
negative sense viral-like RNA was under the control of the human polymerase I promoter. To 305 
create the series of truncation mutant mini-genome constructs truncated versions of the 150 nt 306 
BHA coding regions at either or both termini were amplified using specific primer sets, these PCR 307 
products were fused to the 3’ or 5’ non-coding region by overlapping PCR followed by insertion of 308 
the eGFP coding sequence by overlapping PCR. The resultant products were inserted into pHH-21 309 
as above. All primer sequences are available upon request. For creation of mutant viruses 310 
synonymous mutations were introduced into the BHA open reading frame within the pAB-HA 311 
reverse genetics plasmid by site-directed mutagenesis and the resultant plasmids substituted into 312 
the reverse genetics system. The presence of the desired mutations were confirmed by DNA 313 
sequencing. To generate the pHH-BHA wt and pHH-BHA-3m30/5m30 plasmids total vRNA was 314 
extracted from rBHA wt or rBHA-3m30/5m30 virus and vRNA segment four was amplified by 315 
reverse transcriptase PCR. The resultant cDNA was inserted into the pHH-21 plasmid in a 316 
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negative sense orientation between the human RNA polymerase I promoter and terminator 317 
sequences using BsmBI restriction sites. Segment four sequences were confirmed by DNA 318 
sequencing. 319 
 320 
Mini-genome assay 321 
To test expression of GFP from the mini-genome plasmids, 293T cells in 12-well plates were 322 
transfected with 500 ng of pAB expression plasmids encoding PB1, PB2, PA and NP of 323 
B/Yamanashi/98 virus and 1 µg of each mini-genome construct. 24 hours post-transfection cells 324 
were fixed in 5% formaldehyde and GFP expression was observed at 20x magnification using a 325 
Nikon Microphot-FXA fluorescence microscope. Cell nuclei were stained with 1 µg/ml 4',6-326 
diamidino-2-phenylindole (DAPI) and the total number of cells in each panel was determined by 327 
manual counting using ImageJ. GFP-positive cells were manually counted and the percentage of 328 
the total cell number positive for GFP was calculated. All samples were analysed in triplicate 329 
experiments. 330 
 331 
Virus-like particle (VLP) assay 332 
293T cells were transfected with 1 µg of each mini-genome construct and at 24 h.p.t. infected with 333 
B/Yamanashi/98 virus at an MOI of 10. At 16 h.p.i supernatants were harvested, N-acetyl trypsin-334 
treated at 37 °C for 30 mins, serially 2-fold diluted and placed on MDCK cells. At 10 h.p.i cells were 335 
either analysed by immunofluorescence or FACS. For immunofluorescence analysis cells were 336 
fixed in 5% formaldehyde, permeabilised in PBS/0.5% Triton X-100/0.5% NP40, blocked in PBN 337 
blocking buffer (PBS/1% BSA/0.02% sodium azide) for 1 h at room temperature and stained with 338 
an anti-BNP monoclonal antibody (Abcam) followed by an anti-mouse Texas-red conjugated 339 
secondary antibody. Cell nuclei were stained with DAPI and samples analysed at 20x 340 
magnification using a Nikon Microphot-FXA fluorescence microscope. For FACS analysis cells 341 
were treated with PBS/EDTA to gain single cell suspensions, fixed in 5% formaldehyde, stained 342 
with the anti-BNP monoclonal antibody and anti-mouse Texas-red conjugated secondary antibody 343 
in suspension and subjected to FACS analysis to determine percentages of antigen-positive cells 344 
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(red) that also expressed GFP. 5000 cells were counted per sample and each sample was 345 
performed in duplicate. 346 
 347 
Virus replication kinetics 348 
MDCK cells were infected with either rBHA wt (wild-type) or mutant viruses at an MOI of 0.001 and 349 
supernatant samples harvested every 12 h until 72 hours post-infection. The infectivity of the 350 
samples was determined by plaque assay titration on MDCK cells. Results represent the average 351 
of three independent experiments ± S.D. 352 
 353 
Particle to infectivity ratio analysis 354 
The approximate number of virus particles in virus stocks was estimated by heamagglutination 355 
assay. Virus samples were serially two-fold diluted in PBS in rows of a V-bottomed 96-well plate in 356 
50 µl volumes per well. 50 µl of chicken red blood cells (1 % diluted in PBS) were added to each 357 
well, mixed and incubated at 4 °C until haemagglutination was observed. The reciprocal of the final 358 
dilution of virus to display haemagglutination was used to determine the HA titre per ml of each 359 
virus. As approximately 1x106 virus particles are required to achieve an HA titre of 1 (Donald & 360 
Isaacs, 1954), the HA titres of the virus stocks were multiplied by 1x106 to determine the number of 361 
virus particles per ml in each sample. The infectious titre of each sample (pfu/ml) was determined 362 
by plaque assay titration on MDCK cells. The particle to infectivity ratio (particles/ml : plaque 363 
forming units/ml) was determined for each sample. 364 
 365 
Viral protein analysis by SDS-PAGE 366 
To analyse BHA mRNA transcription and protein expression levels from rBHA wt or rBHA-367 
3m30/5m30 vRNA segment four, 1 µg of the pHH-BHA or pHH-BHA3m30/5m30 plasmids 368 
(described above) were transfected into 293T cells in a 12 well plate alongside 500 ng of pAB 369 
expression plasmids encoding PB1, PB2, PA and NP of B/Yamanashi/98 virus. 24 hours post-370 
transfection cells were lysed in 2x disruption buffer (6 M urea, 2 M β-mercaptoethanol, 4% sodium 371 
dodecyl sulphate), proteins separated by SDS-PAGE and transferred to Immobilon-FL 372 
polyvinylidene difluoride membranes (Millipore). Membranes were blocked in blocking buffer (PBS, 373 
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0.1% Tween 20, 5% dried milk) and incubated with an anti-B/Hong Kong/73 polyclonal antisera (to 374 
detect viral BHA and BNP proteins) or an anti-actin monoclonal antibody. Protein detection was 375 
performed using IRDye 680- or IRDye 800-conjugated secondary antibodies (Licor) on an Odyssey 376 
CLx near infrared scanner (Licor), images were collected and protein band intensities were 377 
quantified using ImageStudio (Licor).  378 
 379 
To analyse virion protein content 500 000 HA units of rBHA wt and rBHA-3m30/5m30 viruses were 380 
purified by sucrose gradient ultracentrifugation. Virus samples were placed onto a 30% sucrose 381 
cushion and subjected to ultracentrifugation at 112 000 x g for 2.5 h at 4 °C. Pelleted viruses were 382 
resuspended in 500 µl NTE buffer (150mM NaCl, 10mM Tris-HCl pH 7.5, 1mM EDTA) and placed 383 
onto a continuous 30-60% sucrose gradient, followed by ultracentrifugation at 112 000 x g for 2.5 h 384 
at 4 °C. Virus bands were extracted from the gradient and pelleted by ultracentrifugation at 112 385 
000 x g for 2 h at 4 °C. Purified virus pellets were resuspended in 50 µl NTE buffer. All virus 386 
purifications were performed in triplicate. Viral proteins in 5 µl of each virus sample were then 387 
separated by SDS-PAGE and analysed by coomassie staining or immunoblotting using the anti-388 
B/Hong Kong/73 polyclonal antisera as described above. Protein bands were detected and 389 
quantified for BHA, BNP and BM1.  390 
 391 
Analysis of virion vRNA content by quantitative reverse transcriptase-PCR 392 
Total vRNA was extracted from three separate samples of rBHA wt or rBHA-3m30/5m30 virus 393 
(5.12 x109 particles for each virus as determined by haemagglutination assay). vRNA segments 394 
four, five and eight were reverse transcribed using gene-specific primers and RevertAid Premium 395 
Reverse Transcriptase (Thermo Scientific). For qPCR viral gene-specific primers (sequences 396 
available on request) were designed to amplify a 150 nt fragment of DNA and various 397 
concentrations of primers were optimised against each other by qPCR using various 398 
concentrations of pAB-HA, pAB-NP or pAB-NS as standardized templates. cDNAs generated by 399 
reverse transcription were then assayed by qPCR using serial four-fold dilutions of cDNA and 400 
appropriate concentrations of gene-specific primers using Precision Mastermix (Primer Design) on 401 
a Stratagene Mx3005P real-time PCR thermocycler. A standard curve was generated using serial 402 
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10-fold dilutions of pAB-HA, pAB-NP or pAB-NS and used to convert ct values into cDNA 403 
concentrations.  404 
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 486 
Figure legends 487 
Figure 1 488 
The first and last 150 nucleotides of the BHA coding region of the influenza B virus vRNA 489 
segment four are required for efficient genome packaging. (a) Schematic diagram of the HA-490 
GFP mini-genome constructs in a vRNA-like 3’-5’ negative sense orientation. HA(150)GFP(150) 491 
contains the first and last 150 nucleotides of the BHA coding regions of B/Yamanashi/98 virus 492 
vRNA segment four (white) flanked by the 3’ and 5’ non-coding regions (grey) with the GFP open 493 
reading frame (green) inserted in frame between the BHA coding regions. A translation termination 494 
codon was inserted after the GFP ORF. The mutant constructs contained truncations in the BHA 495 
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coding regions at either the 3’ or 5’ end of the vRNA segment. All constructs were inserted into the 496 
pHH-21 vector under the control of the human RNA polymerase I promoter and terminator 497 
resulting in the expression of negative sense mini-genome viral-like RNAs. (b) GFP expression 498 
from each HA-GFP construct in a mini-genome replication assay. 293T cells were transfected with 499 
1 µg of each mini-genome construct along with plasmids expressing the B/Yamanashi/98 virus 500 
polymerase complex and BNP proteins. At 24 hours post-transfection (h.p.t.) GFP expression was 501 
observed at 20x magnification. Cell nuclei were stained with DAPI and the total number of cells in 502 
each panel was determined by manual counting using ImageJ. GFP-positive cells were manually 503 
counted and the percentage of the total cell number positive for GFP was calculated. The 504 
percentages were calculated from three independent experiments and are shown in the white 505 
boxes in each panel ± S.D. (c and d) The packaging efficiency of each HA-GFP segment into 506 
virus-like particles (VLPs). 293T cells were transfected with 1 µg of each mini-genome construct 507 
and at 24 h.p.t. infected with B/Yamanashi/98 virus at an MOI of 10. Cells were monitored for GFP 508 
expression and at 16 hours post-infection (h.p.i.) all samples demonstrated GFP expression in 70-509 
80% of cells. Supernatants were then harvested and N-acetyl trypsin-treated. Samples were 510 
serially 2-fold diluted and placed on MDCK cells for 10 hours. At 10 h.p.i. cells were fixed, 511 
permeabilised and stained with an anti-BNP antibody followed by a Texas-red conjugated 512 
secondary antibody. Representative images of GFP and viral antigen staining by 513 
immunofluorescence at 20x magnification are shown in (c) for four of the VLP-containing 514 
supernatants. Nuclei were stained with DAPI. (d) FACS analysis was performed to quantify the 515 
number of antigen positive cells that were also expressing GFP. 5000 cells were analysed per 516 
sample. The percentage of antigen-positive HA(150)GFP(150) VLP-infected cells that also 517 
expressed GFP was set at 100% packaging efficiency and the efficiency of all other constructs was 518 
determined as a percentage of this. Error bars represent the average of two independent 519 
experiments ± S.D. 520 
 521 
Figure 2 522 
Synonymous mutations in both the 3’ and 5’ coding regions of segment four vRNA lead to 523 
virus attenuation. (a) Schematic diagram of mutations inserted into B/Yamanashi/98 virus vRNA 524 
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segment four by reverse genetics. The RNA sequence is shown in positive sense mRNA 525 
orientation to highlight the lack of protein coding changes. The first and last 60 nucleotides of the 526 
BHA coding region are shown (nucleotides 1-60 and 1706-1766 respectively) in the mRNA-sense 527 
orientation with the corresponding amino acid sequence indicated. Synonymous mutations were 528 
inserted into the 3’ end of the vRNA (ie the 5’ end of the mRNA) between nucleotides 1-30 (3m30 529 
mutations) or 31-60 (3m60 mutations) of the BHA coding region, and into the 5’ end of the vRNA 530 
between nucleotides 1706-1736 (5m60 mutations) or 1737-1766 (5m30 mutations). Mutations are 531 
capitalised, highlighted and underlined. Wt = wild-type segment four sequence. (b) Multistep 532 
growth curve analysis of single site mutant viruses. MDCK cells were infected with wt and the four 533 
mutant viruses containing single site mutations (eg 3m30 mutations) at an MOI of 0.001, samples 534 
harvested every 12 hours until 72 h.p.i. and infectious titres determined by plaque assay. Results 535 
show the average of three independent experiments ± S.D. (c) Multistep growth curve analysis of 536 
double site mutant viruses. MDCK cells were infected with wt and mutant viruses containing 537 
double site mutations and replication kinetics determined as in (b). (d) Particle to infectivity 538 
analysis of the mutant virus panel. Stocks of wt and mutant viruses were titrated by plaque assay 539 
and haemagglutination assay. Particle number was calculated based on 1 HA unit requiring 540 
approximately 106 virus particles (Donald & Isaacs, 1954). The particle to infectivity ratio 541 
(particles/ml : plaque forming units/ml) was determined for each virus.  (e) Particle to infectivity 542 
analysis of 3m30 mutation-containing viruses from growth curve samples in (b) and (c). Particle to 543 
infectivity ratios were determined for the 36 h and 48 h growth curve samples for wt and mutant 544 
viruses containing the 3m30 mutations. Results show the average of three independent 545 
experiments ± S.D. 546 
 547 
Figure 3 548 
The 3m30/5m30 mutations do not affect mRNA synthesis/protein production but reduce the 549 
packaging efficiency of vRNA segment four. (a) Sequence alignment of influenza B virus vRNA 550 
segment four sequences. The 3m30, 3m60, 5m30 and 5m60 regions of the influenza B virus vRNA 551 
segment four indicated in Fig. 2(a) (shown in positive sense orientation) were analysed in the 552 
published sequences of multiple viruses isolated between 1940 and 2014. Sequences were 553 
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extracted from the NCBI Influenza Virus Sequence Database and aligned using Geneious 554 
software. Nucleotide differences from the consensus sequence are indicated with identical 555 
nucleotides shown as dots. (b) BHA protein expression is unaffected by the 3m30/5m30 mutations. 556 
Wt and mutant vRNA segment four were cloned into the pHH-21 plasmid under the control of the 557 
human RNA polymerase I promoter, and transfected into 293T cells alongside plasmids 558 
expressing the viral polymerase complex and BNP proteins. 24 h.p.t. cells were lysed and proteins 559 
detected by immunoblotting using an anti-B/Hong Kong/73 polyclonal antibody (to detect BHA and 560 
BNP proteins) and an anti-actin antibody (as a loading control). Images were obtained using an 561 
Odyssey CLx NIR scanner. Results show three independent transfections for each construct. (c) 562 
Quantification of protein levels from (b). Image Studio software was used to quantify the protein 563 
bands in (b) in arbitrary units. The BHA and BNP values were normalised against the actin value 564 
for each sample. Results show the average of three independent transfections ± S.D. * = p > 0.05. 565 
(d) Analysis of viral proteins within purified virus particles. 500 000 HA units of rBHA wt and rBHA-566 
3m30/5m30 viruses were purified by sucrose gradient ultracentrifugation. Proteins within purified 567 
viruses were separated by SDS-PAGE and analysed by coomassie staining. Three individual 568 
preparations are shown for each virus. (e) Quantification of viral proteins within purified virus 569 
particles. Viral proteins in the three preparations of rBHA wt and rBHA-3m30/5m30 viruses from (d) 570 
were analysed by immunoblotting as in (b). Protein bands were detected and quantified for BHA, 571 
BNP and BM1. As BM1 is the major structural component of the virus all viral proteins were 572 
normalised against BM1 levels (set at 100% for each virus). Results show the average of the three 573 
virus preparations ± S.D. * = p > 0.05, ** = p < 0.0005. (f) Quantification of vRNA within virus 574 
particles. vRNA was extracted from 5.12 x109 rBHA wt and rBHA-3m30/5m30 virus particles 575 
(determined by haemagglutination assay) and segments 4, 5 and 8 amplified by quantitative 576 
reverse transcriptase PCR. Levels of each rBHA-3m30/5m30 vRNA segment are expressed as a 577 
percentage of rBHA wt levels and represent three independent experiments ± S.D. * = p > 0.05, ** 578 
= p < 0.0005, *** = p = 0.05.  579 
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